Optimize Financial Inc Invests $444,000 in United Therapeutics Corporation $UTHR

Optimize Financial Inc acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,058 shares of the biotechnology company’s stock, valued at approximately $444,000.

Several other large investors have also recently made changes to their positions in the business. AQR Capital Management LLC grew its holdings in shares of United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the last quarter. Invesco Ltd. boosted its position in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after buying an additional 419,588 shares during the period. Assetmark Inc. grew its stake in shares of United Therapeutics by 38.1% during the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares during the last quarter. Norges Bank bought a new position in United Therapeutics during the 2nd quarter worth approximately $136,453,000. Finally, Amundi increased its stake in United Therapeutics by 3.6% in the 2nd quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock worth $107,113,000 after purchasing an additional 12,633 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent analyst reports. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a report on Wednesday, October 29th. Royal Bank Of Canada boosted their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. Wells Fargo & Company raised their target price on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Finally, HC Wainwright upped their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $509.50.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $470.95, for a total transaction of $10,596,375.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christopher Causey sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total value of $510,000.00. Following the completion of the transaction, the director directly owned 4,190 shares in the company, valued at $2,136,900. The trade was a 19.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 537,914 shares of company stock worth $257,813,558 over the last 90 days. 10.30% of the stock is currently owned by insiders.

United Therapeutics Trading Up 0.9%

Shares of UTHR stock opened at $482.59 on Thursday. The company’s fifty day moving average price is $486.95 and its 200-day moving average price is $424.86. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $519.99. The stock has a market cap of $20.78 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 2.54 and a beta of 0.85.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.